Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Streptococcus salivarius K12 and Reduced Secondary Bacterial Pneumonia

Doses used in studies

CFU/day: 2 billion (median 2 billion, IQR 2 billion–2 billion) — 1 study

Time to effect

Median: 7 days · IQR 7 days–7 days · Range 7 days–7 days — Reported in 1 of 1 study

1 of 1 paper

Oral Probiotic Containing Streptococcus salivarius K12 and Lactobacillus brevis CD2 for Preventing Bacterial Pneumonia in Severe COVID-19: Randomized Clinical Trial.
- 2025-11-12
- RCT · n = 60
- The journal of contemporary dental practice 26(10)
- - Jonathan R Lauxen
  - Sidia M Callegari-Jacques
  - Augusto S Mombelli
  - Amanda Prando
  - Tiago T Simon
  - Fernando Fornari
- PubMed: 41526312
- DOI: 10.5005/jp-journals-10024-3954
3 Insights on
- Reduced Secondary Bacterial Pneumonia
- High evidence
- Clinical
The incidence of secondary bacterial pneumonia was 35% for probiotics and 54% for placebo [relative risk: 0.64 (95% CI: 0.34-1.22)].
Effect
Neutral
Effect size
Large
Significant
No
Dose
2 billion colony-forming units every 8 hours